The CF drug discovery landscape has recently expanded with the identification of multiple novel modulators of mutant CFTR.14, 31–33 Therefore, a priority for the field is to rank the efficacy of emerging compounds relative to approved drugs such as ivacaftor (VX-770) in relevant tissues such as the airway epithelium. The gene discussed is CFTR; the disease is cystic fibrosis.